Literature DB >> 27379972

Adenomyosis: a systematic review of medical treatment.

A Pontis1, M N D'Alterio2, S Pirarba2, C de Angelis3, R Tinelli4, S Angioni2.   

Abstract

Adenomyosis is a heterogeneous gynaecologic condition with a range of clinical presentations, the most common being heavy menstrual bleeding and dysmenorrhoea; however, patients can also be asymptomatic. Several studies support the theory that adenomyosis results from invasion of the endometrium into the myometrium, causing alterations in the junctional zone. These changes are commonly seen on imaging studies, such as transvaginal ultrasound and magnetic resonance imaging. The aim of this review is to discuss the medical approach to the management of adenomyosis symptoms, including pain and abnormal uterine bleeding. The standard treatment of adenomyosis is hysterectomy, but there is no medical therapy to treat the symptoms of adenomyosis while still allowing patients to conceive. Medical therapies using suppressive hormonal treatments, such as continuous use of oral contraceptive pills, high-dose progestins, selective oestrogen receptor modulators, selective progesterone receptor modulators, the levonorgestrel-releasing intrauterine device, aromatase inhibitors, danazol, and gonadotrophin receptor hormone agonists can temporarily induce regression of adenomyosis and improve the symptoms.

Entities:  

Keywords:  Adenomyosis; GnRH agonist; aromatase inhibitors; danazol; endometriosis; levonorgestrel-releasing intrauterine device; oral contraceptive; progestins

Mesh:

Year:  2016        PMID: 27379972     DOI: 10.1080/09513590.2016.1197200

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  24 in total

1.  Is LNG-IUS the One-Stop Answer to AUB?

Authors:  Jayashree Nayar; Sobha S Nair; Nisha Annie George
Journal:  J Obstet Gynaecol India       Date:  2017-09-12

Review 2.  Adverse bone effects of medications used to treat non-skeletal disorders.

Authors:  N B Watts
Journal:  Osteoporos Int       Date:  2017-07-27       Impact factor: 4.507

3.  [Role of estrogen, estrogen receptors, and aromatase in the pathogenesis of uterine adenomyosis].

Authors:  Yu-Yan Zeng; Yong-Ge Guan; Kun-Yin Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-03-20

4.  Prevalence of adenomyosis in women undergoing hysterectomy for abnormal uterine bleeding, pelvic pain or uterine prolapse - A retrospective cohort study.

Authors:  Harald Krentel; Rudy Leon De Wilde
Journal:  Ann Med Surg (Lond)       Date:  2022-05-23

5.  Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.

Authors:  Marissa J Harmsen; Caroline F C Wong; Velja Mijatovic; Arjan W Griffioen; Freek Groenman; Wouter J K Hehenkamp; Judith A F Huirne
Journal:  Hum Reprod Update       Date:  2019-09-11       Impact factor: 15.610

6.  Quercetin Inhibits Adenomyosis by Attenuating Cell Proliferation, Migration and Invasion of Ectopic Endometrial Stromal Cells.

Authors:  Wenbin Xu; Yizuo Song; Kehan Li; Biyun Zhang; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2020-09-21       Impact factor: 4.162

7.  Anti-Müllerian hormone level may predict successful pregnancy after adenomyomectomy in patients with infertility due to adenomyosis.

Authors:  Seyeon Won; Ji Young Hwang; Nara Lee; Miseon Kim; Mi Kyoung Kim; Mi-La Kim; Bo Seong Yun; Seok Ju Seong; Yong Wook Jung
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

8.  Menorrhagia and Uterine Volume Associated with Lower Urinary Tract Symptoms in Patients with Adenomyosis.

Authors:  Ting Li; Xiao-Xuan Xu; Yi Dai; Jun-Ji Zhang; Jing-He Lang; Jin-Hua Leng
Journal:  Chin Med J (Engl)       Date:  2017-07-05       Impact factor: 2.628

9.  Transcriptome analysis of endometrial tissues following GnRH agonist treatment in a mouse adenomyosis model.

Authors:  Song Guo; Xiaowei Lu; Ruihuan Gu; Di Zhang; Yijuan Sun; Yun Feng
Journal:  Drug Des Devel Ther       Date:  2017-03-09       Impact factor: 4.162

10.  Ultra-Long GnRH Agonist Protocol During IVF/ICSI Improves Pregnancy Outcomes in Women With Adenomyosis: A Retrospective Cohort Study.

Authors:  Jie Lan; Yaoqiu Wu; Zexuan Wu; Yingchen Wu; Rong Yang; Ying Liu; Haiyan Lin; Xuedan Jiao; Qingxue Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-31       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.